 SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 GLOBE NEWSWIRE -- CareDx, Inc. Nasdaq: CDNA, a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it intends to offer and sell, subject to market and other conditions, up to 175.0 million of shares of its common stock in an underwritten public offering. CareDx also expects to grant the underwriters of the offering a 30 day option to purchase up to an additional 26.25 million of shares of its of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx. 